Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage 0 bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-8 of 8 for your search:
Start Over
Everolimus and Gemcitabine Hydrochloride in Treating Patients With Refractory Primary or Secondary In Situ Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-165, NCI-2010-02341, NCT01259063
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-801-01-12, NCI-2013-00693, NCT01625260
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HS410-101, NCI-2014-01420, NCT02010203
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG-naive Non-Muscle Invasive Bladder Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA-ALT-803-01-14, NCI-2014-02463, NCT02138734
BCG Intravesical Solution and Sunitinib Malate in Treating Patients With Bladder Cancer
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: UMCC 2008.086, NCI-2011-03616, NCT00794950
Dovitinib Lactate in Treating Patients With Refractory or Stage 0-I Bladder Cancer With FGFR3 Mutations or Overexpression
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GU12-157, NCI-2013-00610, 1211009949, CTKI258AUS17T, NCT01732107
BCG Solution in Treating Patients with Non-muscle Invasive Urothelial Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-174, NCI-2014-02528, NCT02281383
Start Over